Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data
Authors' conclusion
The risk of serious cardiac adverse drug reactions to COVID-19 vaccines is low and the benefit of active immunization against that disease seems to outweigh the potential risk of serious post-vaccination cardiac adverse drug reactions.
Study context
- Population
- Recipients of COVID-19 vaccines in the European Economic Area
- Participants
- 772,228,309 doses
- Exposure
- Comirnaty vs Spikevax vs Vaxzevria vs Jcovden vs Nuvaxovid
- Outcome
- Suspected serious cardiac post-vaccination adverse drug reactions per million doses
Methodological detailsretrospective, EudraVigilance pharmacovigilance database, ECDC Vaccine Tracker dose data
- Retrospective
- EudraVigilance pharmacovigilance database
- ECDC Vaccine Tracker dose data
Main finding
As reported in the abstract
Any serious cardiac adverse drug reaction
- Frequency of most investigated ADRs very rare
- <100/1 000 000 doses
Observational data: associations, not effects.
Further findings
Most common complications
- Syncope, arrhythmia, tachycardia, palpitations, angina pectoris, hypertension, myocarditis, thrombosis and PE
Original publication
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data. Eur Heart J Cardiovasc Pharmacother. Published 22 August 2024. doi:10.
Summarised from the published abstract; every number is checked against it